Invention Grant
- Patent Title: 1-cyano-pyrrolidine compounds as USP30 inhibitors
-
Application No.: US16419558Application Date: 2019-05-22
-
Publication No.: US10689345B2Publication Date: 2020-06-23
- Inventor: Alison Jones , Mark Kemp , Martin Stockley , Karl Gibson , Gavin Whitlock
- Applicant: Mission Therapeutics Limited
- Applicant Address: GB Cambridge
- Assignee: Mission Therapeutics Limited
- Current Assignee: Mission Therapeutics Limited
- Current Assignee Address: GB Cambridge
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@1831e281 com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@74268d31
- Main IPC: C07D211/56
- IPC: C07D211/56 ; C07D403/12 ; C07D401/14 ; C07D413/14 ; C07D401/12 ; C07D403/14 ; C07D413/12 ; C07D417/12 ; C07D417/14 ; C07D471/04 ; C07D487/04 ; C07D207/14
Abstract:
The present invention relates to novel compounds and method for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (II) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R8, R9, R10, R12, Z, Y and m are as defined herein.
Public/Granted literature
- US20190322624A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS Public/Granted day:2019-10-24
Information query
